Introducing the BenevolentAI and UCL PhDs

Inviting students to train as the experts of tomorrow in applying machine learning to human genetics and electronic health records. The UCL Centre for Translational Genomics (CTG) and Institute for Health Informatics (IHI) are international centres of excellence for research in these two areas and we are excited about further strengthening our already established links with them both.

Read More
New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca. This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

Read More
BLOGCeline LatureLondon
Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated. We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

Read More
A new chapter @ BenevolentAI

Today marks my first official day as Group CEO at BenevolentAI. For me, it is the next step of a journey, one that has encompassed amazing experiences building some of the biggest technology brands on the planet. Yet none of them had the same potential to transform our lives for the better as we have here at BenevolentAI.

Read More
Counting down to the BenevolentAI Award

It’s now only a number of days until we announce the winner of the first BenevolentAI award on March 28th. Since applications closed in late January, the process has been one my fellow judges, Aisling Burnand, CEO of Association of Medical Research Charities (AMRC), and Neil Lawrence, Director of Machine Learning of Amazon Research Cambridge and I have found enjoyable, insightful and richly rewarding.

Read More